SYRE vs. PCRX, MIRM, COLL, BLTE, PRTA, MNKD, GYRE, IRWD, VRNA, and ABCL
Should you be buying Spyre Therapeutics stock or one of its competitors? The main competitors of Spyre Therapeutics include Pacira BioSciences (PCRX), Mirum Pharmaceuticals (MIRM), Collegium Pharmaceutical (COLL), Belite Bio (BLTE), Prothena (PRTA), MannKind (MNKD), Gyre Therapeutics (GYRE), Ironwood Pharmaceuticals (IRWD), Verona Pharma (VRNA), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical preparations" industry.
Pacira BioSciences (NASDAQ:PCRX) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends.
Pacira BioSciences has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Pacira BioSciences had 12 more articles in the media than Spyre Therapeutics. MarketBeat recorded 28 mentions for Pacira BioSciences and 16 mentions for Spyre Therapeutics. Spyre Therapeutics' average media sentiment score of 0.42 beat Pacira BioSciences' score of 0.34 indicating that Pacira BioSciences is being referred to more favorably in the media.
Pacira BioSciences has a net margin of 10.34% compared to Pacira BioSciences' net margin of 0.00%. Spyre Therapeutics' return on equity of 12.98% beat Pacira BioSciences' return on equity.
Pacira BioSciences received 799 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 71.81% of users gave Pacira BioSciences an outperform vote.
Pacira BioSciences has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.93, suggesting that its stock price is 193% more volatile than the S&P 500.
Pacira BioSciences presently has a consensus target price of $47.40, indicating a potential upside of 56.02%. Spyre Therapeutics has a consensus target price of $43.17, indicating a potential upside of 16.67%. Given Spyre Therapeutics' higher possible upside, analysts plainly believe Pacira BioSciences is more favorable than Spyre Therapeutics.
99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Pacira BioSciences beats Spyre Therapeutics on 14 of the 17 factors compared between the two stocks.
Get Spyre Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SYRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spyre Therapeutics Competitors List
Related Companies and Tools
